drugset / Trial / NCT01239992

Effect of Niacin/Laropiprant on Postprandial Lipoprotein Metabolism in Patients With Dyslipoproteinemia

NCT01239992

Phase 4 Terminated 12 enrolled Ludwig-Maximilians - University of Munich
NaSingle-groupOpen-labelTreatment

Summary

The study is designed to evaluate the effect of Niacin/Laropiprant on postprandial lipoprotein metabolism, postprandial glucose metabolism, postprandial monocyte function, and postprandial biomarkers of endothelial dysfunction and inflammation.

Timeline

Start
2011-06
Primary completion
2013-01
Completion
2013-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Niacin Small molecule 2000 mg
Subject laropiprant Small molecule 40 mg